KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2025)

Historic Convertible Debt for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Q3 2025 value amounting to $1.0 billion.

  • Alnylam Pharmaceuticals' Convertible Debt rose 162.38% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 162.38%. This contributed to the annual value of $1.0 billion for FY2024, which is 37.67% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Convertible Debt stood at $1.0 billion for Q3 2025, which was up 162.38% from $1.0 billion recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Convertible Debt's 5-year high stood at $1.0 billion during Q3 2025, with a 5-year trough of $1.0 billion in Q3 2022.
  • Its 4-year average for Convertible Debt is $1.0 billion, with a median of $1.0 billion in 2024.
  • Data for Alnylam Pharmaceuticals' Convertible Debt shows a peak YoY increase of 162.38% (in 2025) and a maximum YoY decrease of 37.49% (in 2025) over the last 5 years.
  • Over the past 4 years, Alnylam Pharmaceuticals' Convertible Debt (Quarter) stood at $1.0 billion in 2022, then increased by 0.38% to $1.0 billion in 2023, then increased by 0.38% to $1.0 billion in 2024, then increased by 1.53% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.